GSK: March Madness Lineup

DailyInvestors

Invested

Community Contributor

Published

25 Feb 25

Updated

20 Mar 25

DailyInvestors's Fair Value

UK£78.00

81.9% undervalued

20 Mar

UK£14.15

-11.3%

2.3%

Author's Valuation

UK£78.0

81.9% undervalued

DailyInvestors's Fair Value

Narrative

Updates1

Shared on13 Mar 25

DailyInvestors made no meaningful changes to valuation assumptions.

DailyInvestors'sFair Value

UK£78.0

81.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.00%

Pharma revenue growth rate

1.09%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.82%

Calculation

UK£18.93b

Earnings '29

23.02x

PE Ratio '29

UK£435.80b

Market Cap '29

UK£435.80b

Market Cap '29

4.21b

No. shares '29

UK£103.62

Share Price '29

UK£103.62 Share Price '29

Discounted to 2024 @ 6.40% p.a.

UK£75.97

Fair Value '24